biostudies-literatureRodgers LRMedical Research CouncilNational Institute for Health Research (NIHR)Wellcome Truste017989https://www.ebi.ac.uk/biostudies/studies/S-EPMC5652624biostudies-literatureUnknown7(10)<h4>Purpose</h4>This is a retrospective cohort study using observational data from anonymised primary care records. We identify and extract all patients with type 2 diabetes and associated clinical data from the Clinical Practice Research Datalink (CPRD) to inform models of disease progression and stratification of treatment.<h4>Participants</h4>Data were extracted from CPRD on 8 August 2016. The initial data set contained all patients (n=313 485) in the database who had received a type 2 diabetes medication. Criteria were applied to identify and exclude those with type 1 diabetes, polycystic ovarian syndrome or other forms of diabetes (n=40 204), and for data quality control (n=12). We identified 251 338 patients for inclusion in future analyses of diabetes progression and treatment respoBMJ openCohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes.PMC5652624NF-SI-0611-10219MR/K005707/1098395/Z/12/ZNF-SI-0616-10080MR/N00633X/1Weedon MNHattersley ATHenley WERodgers LRShields BMfalseCohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes.<h4>Purpose</h4>This is a retrospective cohort study using observational data from anonymised primary care records. We identify and extract all patients with type 2 diabetes and associated clinical data from the Clinical Practice Research Datalink (CPRD) to inform models of disease progression and stratification of treatment.<h4>Participants</h4>Data were extracted from CPRD on 8 August 2016. The initial data set contained all patients (n=313 485) in the database who had received a type 2 diabetes medication. Criteria were applied to identify and exclude those with type 1 diabetes, polycystic ovarian syndrome or other forms of diabetes (n=40 204), and for data quality control (n=12). We identified 251 338 patients for inclusion in future analyses of diabetes progression and treatment respo2017-01-01T00:00:00Z2017 Oct2026-07-15T21:31:31.587Z2026-07-09T10:14:19.557ZS-EPMC56526242902584610.1136/bmjopen-2017-017989